Skip to main content Accessibility help
×
Home

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

  • D.G.S. Perahia (a1) (a2), F. Wang (a3), C.H. Mallinckrodt (a3), D.J. Walker (a3) and M.J. Detke (a3) (a4) (a5)...

Abstract

Objective:

Duloxetine doses of 80 and 120 mg/day were assessed for efficacy and safety in the treatment of major depressive disorder (MDD).

Methods:

In this randomized, double-blind trial, patients age ≥ 18 meeting DSM-IV criteria for MDD were randomized to placebo (N = 99), duloxetine 80 mg/day (N = 93), duloxetine 120 mg/day (N = 103), or paroxetine 20 mg/day (N = 97). The primary outcome measure was mean change from baseline in the 17-item Hamilton rating scale for depression (HAMD17) total score after 8 weeks of treatment; a number of secondary efficacy measures also were assessed. Safety and tolerability were assessed via collection and analysis of treatment–emergent adverse events (TEAEs), vital signs, and weight. The Arizona sexual experiences scale was used to assess sexual functioning. Patients who had a ≥ 30% reduction from baseline in the HAMD17 total score at the end of the acute phase entered a 6-month continuation phase where they remained on the same treatment as they had taken during the acute phase; efficacy and safety/tolerability outcomes were assessed during continuation treatment.

Results:

More than 87% of patients completed the acute phase in each treatment group. Duloxetine-treated patients (both doses) showed significantly greater improvement (P < 0.05) in the HAMD17 total score at week 8 compared with placebo. Paroxetine was not significantly different from placebo (P = 0.089) on mean change on the HAMD17. Duloxetine 120 mg/day also showed significant improvement on most secondary efficacy measures (six of nine) compared with placebo while duloxetine 80 mg/day (three of nine) and paroxetine (three of nine) were significantly superior to placebo on fewer secondary measures. HAMD17 mean change data from this study and an identical sister study were pooled as defined a priori for the purposes of performing a non-inferiority test versus paroxetine. Both duloxetine doses met statistical criteria for non-inferiority to paroxetine. TEAE reporting rates were low in all treatment groups and no deaths occurred in the acute or continuation phases.

Conclusions:

The efficacy of duloxetine at doses of 80 and 120 mg/day in the treatment of MDD was demonstrated. Tolerability, as measured by TEAEs, and safety were similar to paroxetine 20 mg/day and consistent with previous published data on duloxetine in the treatment of MDD.

Copyright

Corresponding author

*Corresponding author. E-mail address: d.perahia@lilly.com (D.G.S. Perahia).

References

Hide All
[1]Nemeroff, C.B., Schatzberg, A.F., Goldstein, D.J., Detke, M.J., Mallinckrodt, C.H., Lu, Y.et al.Duloxetine for the treatment of major depressive disorder Psychopharmacol Bull. 2002; 36:106132.
[2]Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., Demitrack, M.A.Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial J Clin Psychiatry 2002; 63:308315.
[3]Detke, M.J., Lu, Y., Goldstein, D.J., McNamara, R.K., Demitrack, M.A.et al.Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression J. Psychiatr. Res. 2002; 36:383390.
[4]Detke, M.J., Wiltse, C.G., Mallinckrodt, C.H., McNamara, R.K., Demitrack, M.A., Bitter, I.Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Eur. Neuropsychopharmacol 2004; 14:457470.
[5]Goldstein, D.J., Mallinckrodt, C., Lu, Y., Demitrack, M.A.Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial Journal of Clinical Psychiatry 2002; 63:225231.
[6]Goldstein, D.J., Lu, Y., Detke, M., Wiltse, C., Mallinckrodt, C., Demitrack, M.A.Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine J. Clin. Psychopharmacol 2004; 24:389399.
[7]Perahia, D.G., Gilaberte, I., Wang, F., Wiltse, C.G., Huckins, S.A., Clemens, J.W.et al.Duloxetine in the prevention of relapse of major depressive disorder: a double-blind, placebo-controlled study Br. J. Psychiatry 2006; 188:346353.
[8]Khan, A., Schwartz, K.Study designs and outcomes in antidepressant clinical trials Essent Psychopharmacol 2005; 6:221226.
[9]Hamilton, M.A rating scale for depression J. Neurol. Neurosurg Psychiatry 1960; 23:5662.
[10]Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E.et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59(Suppl 20)1998 2233.
[11]Maier, W., Philipp, M.Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale Pharmacopsychiatry 1985; 18:114115.
[12]Faries, D., Herrera, J., Rayamajhi, J., DeBrota, D., Demitrack, M., Potter, W.Z.The responsiveness of the Hamilton Depression Rating Scale J. Psychiatr. Res. 2000; 34:310.
[13]Tollefson, G.D., Holman, S.L.Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression Int. Clin. Psychopharmacol 1993; 8:253259.
[14]Montgomery, S.A., Asberg, M.A new depression scale designed to be sensitive to change Br. J. Psychiatry 1979; 134:382389.
[15]Hamilton, M.The assessment of anxiety states by rating Br. J. Med. Psychol. 1959; 32:5055.
[16]Guy, W. ECDEU. Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM) Rockville MD: National Institute of Mental Health; 1976.
[17]Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A.The measurement of disability Int. Clin. Psychopharmacol 11(Suppl 3)1996 8995.
[18]DeLoach, L.J., Higgins, M.S., Caplan, A.B., Stiff, J.L.The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale Anesth. Analg. 1998; 86:102106.
[19]Barsky, A.J., Wyshak, G., Klerman, G.L.et al.Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients Arch. Gen. Psychiatry 1986; 43:493500.
[20]McGahuey, C.A., Gelenberg, A.J., Laukes, C.A., Moreno, F.A., Delgado, P.L., McKnight, K.M.et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity J. Sex. Marital. Ther. 2000; 26:2540.
[21]Mallinckrodt, C.H., Clark, W.S., David, S.R.Accounting for dropout bias using mixed-effects models J. Biopharm. Stat. 2001; 11:921.
[22]Mallinckrodt, C.H., Clark, W.S., David, S.R.Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF Drug. Inf. J. 2001; 35:12151225.
[23]Lieberman, J.A., Greenhouse, J., Hamer, R.M., Krishnan, K.R., Nemeroff, C.B., Sheehan, D.V.et al.Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy Neuropsychopharmacol 2005; 30:445460.
[24]Leon, A.C.Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology J. Clin. Psychiatry 62(Suppl 4)2001 1216.
[25]Thompson, W., Brunelle, R., Enas, G.et al.Routine laboratory tests in clinical trials Eli Lilly and Company, Indianapolis, IN 1990 163.
[26]Khan, A., Detke, M.J., Khan, S.R.F., Mallinckrodt, C.Placebo Response and Antidepressant Clinical Trial Outcome J. Nerv. Ment. Dis. 2003; 19:211218.
[27]Delgado, P.L., Brannan, S.K., Mallinckrodt, C.H., Tran, P.V., McNamara, R.K., Wang, F.et al.Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder J. Clin. Psychiatry 2005; 66:686692.
[28]Dunner, D.L., Dunbar, G.C.et al.Optimal dose regimen for paroxetine J. Clin. Psychiatry 53(Suppl)1992 2126.
[29]Benkert, O., Szegedi, A., Wetzel, H., Staab, H.J., Meister, W., Philipp, M.Dose escalation vs. continued dose of paroxetine and maptroline: a prospective study in depressed outpatients with inadequate treatment response Acta. Psychiatr. Scand. 1997; 95:288296.
[30]Jenner, P.N.Paroxetine: an overview of dosage, tolerability, and safety Int. Clin. Psychopharmacol. 6(Suppl 4)1992 6980.
[31]Wernicke, J.F., Faries, D., Milton, D., Weyrauch, K.Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods Drug Safety 2005; 28:10571063.

Keywords

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

  • D.G.S. Perahia (a1) (a2), F. Wang (a3), C.H. Mallinckrodt (a3), D.J. Walker (a3) and M.J. Detke (a3) (a4) (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

  • D.G.S. Perahia (a1) (a2), F. Wang (a3), C.H. Mallinckrodt (a3), D.J. Walker (a3) and M.J. Detke (a3) (a4) (a5)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *